Honglian Li
Ph.D, Assistant Researcher
Email：lihonglian@@gdiist.cn
Personal Profile:
Graduated from Tianjin Medical University in 2019, joined Guangdong Institute of Intelligent Science and Technology in July 2025.
Research focus:
Implication of Heparan sulfate in Oxytocin receptor signaling
Publications:
1. Maccarana M, Li B, Li H, Fang J, Yu M, Li JP. Inhibitors of dermatan sulfate epimerase 1 decreased accumulation of glycosaminoglycans in mucopolysaccharidosis type I fibroblasts. Glycobiology, 2024, 34, cwae025
2. Veraldi N, Quadri I, Looij Y, Modernell L, Colliec-Jouault S, Sinquin C, Zykwinska A, Tournier B, Dalonneau F, Vives R, Li H, Li JP, Millet P, Agostini A, Sanches E, Sizonenko S. Beneficial effects of low molecular weight marine polysaccharides in mucopolysaccharidosis IIIA. Carbohydrate Polymers, Volume 320, 2023, 121214
3. Li H, Zhang H, Wenz A, Kang Z, Wang H, Vlodavsky I, Chen X, Li JP. Heparanase modulates
chromatin accessibility. Cells, 2023, 12(6), 891
4. Zhang T, Yu M, Li H, Maccarana M, Zhang W, Shi D, Kan Y, Zhang X, Chi L, Lindahl U, Li H, Li JP, Tan T. Interacting polymer-modification enzymes in heparan sulfate biosynthesis. Carbohydrate Polymers, Volume 299, 2023, 120191
5. Maccarana M, Jia J, Li H, Zhang X, Vlodavsky I and Li JP. Implications of heparanase on heparin synthesis and metabolism in mast cells. Int. J. Mol. Sci. 2022, 23(9), 4821
6. Zhang X, O’Callaghan P, Li H, Tan Y, Zhang G, Barash U, Wang X, Lannfelt L, Vlodavsky I, Lindahl U, Li JP. Heparanase overexpression impedes perivascular clearance of amyloid-ß from murine brain-relevance to Alzheimer’s disease. Acta neuropathol commun. 9, 84 (2021)
7. Gockel LM, Heyes M, Li H, Al Nahain A, Gorzelanny C, Schlesinger M, Holdenrieder S, Li JP, Ferro V, Bendas G. Inhibition of Tumor-Host Cell Interactions Using Synthetic Heparin Mimetics. ACS Applied Materials & Interfaces. 2021, 13 (6), 7080-7093
8. Zhou W & Liu Y & Li HL, Song ZY, Ma Y, Zhu Y. Mass Spectrometry and Computer Simulation Predict the Interactions of AGPS and HNRNPK in Glioma. BioMed Research International. 2021, article 6181936
9. Wu JW, Zhang H, Li WY, Tang X, Li HL, Lu XH, Zheng HZ, MaY, Wang RL. Design potential selective inhibitors for human leukocyte common antigen-related (PTP-LAR) with fragment replace approach. J BIOMOL STRUCT DYN. 2020 Nov; 38 (18): 5338-5348
10. Li HL, Ma Y, Zheng CJ, Jin WY, Liu WS, Wang RL. Exploring the effect of D61G mutation on SHP2 cause gain of function activity by a molecular dynamics study. J BIOMOL STRUCT DYN. 2018, VOL. 36, (14), 3856-3868
11. Jin WY, Ma Y, Li WY, Li HL, Wang RL. Scaffold-based novel SHP2 allosteric inhibitors design using Receptor-Ligand pharmacophore model, virtual screening and molecular dynamics. COMPUT BIOL CHEM. 2018, 73: 179-188
12. Ma Y & Li HL, Chen XB, Jin WY, Zhou H, Ma Y, Wang RL. 3D QSAR Pharmacophore Based Virtual Screening for Identification of Potential Inhibitors for CDC25B. COMPUT BIOL CHEM. 2018, 73:1-12
13. Li HL, Ma Y, Ma Y, Li Y, Chen XB, Dong WL, Wang RL. The design of novel inhibitors for treating cancer by targeting CDC25B through disruption of CDC25B-CDK2/Cyclin A interaction using computational approaches. ONCOTARGET. 2017, Vol. 8, (20), 33225-33240
14. Ma Y, Wei HY, Zhang YZ, Jin WY, Li HL, Zhou H, Cheng XC, Wang RL. Synthesis, bioactivity, 3D- QSAR studies of novel dibenzofuran derivatives as PTP-MEG2 inhibitors. ONCOTARGET. 2017 Jun 13; 8 (24): 38466-38481
